Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. Supreme Court rebuffs opioid maker Insys founder's conviction appeal

Published 06/13/2022, 09:49 AM
Updated 06/13/2022, 07:15 PM
© Reuters. FILE PHOTO: The billionaire founder of Insys Therapeutics Inc. John Kapoor, exits the federal court house after a bail hearing in Phoenix, Arizona , U.S., October 27, 2017.  REUTERS/Conor Ralph/File Photo

By Nate Raymond

(Reuters) -The U.S. Supreme Court on Monday rejected bids by Insys Therapeutics Inc founder John Kapoor and another former executive of the drugmaker to overturn their convictions for conspiring to bribe doctors to prescribe addictive opioids and defraud insurers into paying for them.

The justices turned away appeals by Kapoor, the former Insys executive chairman, and Sunrise Lee, a former regional sales director, of their 2019 convictions by a jury in federal court in Boston on the charge of racketeering conspiracy.

Kapoor, 78, is serving a prison sentence of 5-1/2 years and is the highest-level corporate executive convicted at trial of crimes related to the opioid epidemic that has killed hundreds of thousands of Americans in the past two decades.

"Real people suffered at the hands of these defendants, who put greed and lining their own pockets ahead of patient safety," U.S. Attorney Rachael Rollins (NYSE:ROL), Boston's top federal prosecutor, said in a statement. "They remain convicted felons and justice has been served."

Kapoor's lawyers declined to comment. Peter Horstmann, an attorney for Lee, said he was "very disappointed. She has already completed a one-year prison sentence.

The jury found them guilty of participating in a wide-ranging scheme to bribe doctors nationwide by retaining them to act as speakers at sham events ostensibly meant to educate clinicians about the company's fentanyl spray, Subsys.

Kapoor's lawyers in a petition filed in January with the Supreme Court argued that a non-physician like him cannot be convicted of agreeing with a doctor to illegally distribute drugs if the doctor believed he or she was acting in good faith.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The Boston-based 1st U.S. Circuit Court of Appeals in August 2021 upheld his conviction, as well as the convictions of four other former company officials tried alongside him, including Lee.

The racketeering conspiracy convictions were based on the jury's conclusion that Kapoor and others conspired to commit crimes, including illegally distributing a controlled substance.

The Supreme Court in March heard arguments in two cases involving doctors convicted of unlawfully dispensing opioids about whether jurors should be required to consider if they had good faith reasons to believe their prescriptions were medically valid.

Prosecutors said one of those two doctors, Xiulu Ruan of Alabama, accepted kickbacks from Insys and ran a "pill mill."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.